These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: High dose cytosine arabinoside is a major risk factor for the development of hepatosplenic candidiasis in patients with leukemia.
    Author: Woolley I, Curtis D, Szer J, Fairley C, Vujovic O, Ugoni A, Spelman D.
    Journal: Leuk Lymphoma; 1997 Nov; 27(5-6):469-74. PubMed ID: 9477128.
    Abstract:
    A retrospective study of hepatosplenic candidiasis in patients with acute leukemia from a single centre was performed. The significance of age, sex, type of leukemia, dose of cytosine arabinoside (Ara-C), duration of neutropenia, steroid use and period of therapeutic antibiotics in the development of hepatosplenic candidiasis was analyzed, using logistic regression analysis. Nine of 51 patients had hepatosplenic candidiasis. Ara-C use was highly associated with the development of hepatosplenic candidiasis (p = 0.001); with a high association with a higher dose (p < 0.0001). On the basis of these results consideration should be given to further trial of antifungal prophylaxis for patients receiving high dose Ara-C.
    [Abstract] [Full Text] [Related] [New Search]